Virax Biolabs Group Limited filed a Form 6-K on October 29, 2026, announcing that its wholly owned Chinese subsidiary, Shanghai Xitu Consulting Co., Ltd., has entered into non-exclusive distribution agreements with three companies for its ImmuneSelect research-use immune profiling products.

Key Highlights

  • Three distributors named: AmyJet Scientific Inc., Jiangsu Real-Gen Biotechnology Co., Ltd., and Zhixi (Shanghai) Biotechnology Co., Ltd. have each signed non-exclusive distribution agreements with the company's China subsidiary.
  • Six mainland Chinese markets covered: The agreements create distribution routes across Beijing, Shanghai, Suzhou, Wuhan, and additional markets, according to the filing.
  • AmyJet's scope: AmyJet, which the filing reports has more than 200 international life sciences supplier relationships, will target industrial and biotechnology customers in Beijing, Shanghai, and Hubei.
  • Jiangsu Real-Gen's scope: Jiangsu Real-Gen will target academic, biopharmaceutical, and other research customers in Jiangsu, Anhui, and Shandong, with a regional presence in Suzhou, Nanjing, Hefei, and Jinan.
  • Zhixi's scope: Zhixi adds a targeted Shanghai academic sales channel and shares common ownership with Shanghai KEL Biotech, according to the filing.
  • Initial products: The filing identifies ELISpot assay plates and antigen-specific peptide pools for infectious disease, vaccine, and cellular immunity research as the initial product focus.

Virax Biolabs Expands China Reach via Shanghai Subsidiary Agreements

According to the Form 6-K filed with the U.S. Securities and Exchange Commission on October 29, 2026, Virax Biolabs Group Limited (NASDAQ:VRAX), through its wholly owned subsidiary Shanghai Xitu Consulting Co., Ltd., has executed non-exclusive distribution agreements with three separate Chinese companies. The registrant disclosed this development via a press release dated October 29, 2026, which is included as Exhibit 99.1 to the report.

The filing describes each distributor's designated territory and customer focus. AmyJet Scientific Inc., which the filing states has more than 200 international life sciences supplier relationships and already offers ELISpot and other immunology research reagents, will serve industrial and biotechnology customers in Beijing, Shanghai, and Hubei. Jiangsu Real-Gen Biotechnology Co., Ltd., with presence in Suzhou, Nanjing, Hefei, and Jinan, is designated for academic, biopharmaceutical, and other research customers in Jiangsu, Anhui, and Shandong. Zhixi (Shanghai) Biotechnology Co., Ltd. is focused on the Shanghai academic market and, according to the filing, shares common ownership with Shanghai KEL Biotech, which the filing characterizes as providing relevant research-reagent trading experience.

The filing states that the initial product focus under these agreements is ELISpot assay plates and antigen-specific peptide pools, positioned for infectious disease, vaccine, and cellular immunity research. The registrant noted that local distribution supports commercial expansion "while limiting the need to build a larger direct sales organisation." The Form 6-K was signed by James Foster, Chief Executive Officer, on behalf of Virax Biolabs Group Limited.

What Was Disclosed

Virax Biolabs disclosed three non-exclusive distribution agreements entered into through its China subsidiary, covering six mainland Chinese markets via AmyJet Scientific, Jiangsu Real-Gen Biotechnology, and Zhixi (Shanghai) Biotechnology, with an initial focus on ImmuneSelect immune profiling products.